Contributions
Abstract: EP1473
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Immunology
Background: Evidence continues to accumulate supporting a protective role for vitamin D in multiple sclerosis (MS) risk and progression. However, whether vitamin D immunomodulatory effects can be translated into clinical benefits in patients with MS is still a matter of debate. Finding modulator factors in relation to vitamin D an MS could be helpful for clinicians to optimize individual therapies. We aimed to investigate association between circulating levels of vitamin D and haptoglobin as mediators in inflammatory and autoimmune pathways in different types of MS.
Methods: This crass-sectional study enrolled 72 MS patients. The diagnosis of MS was made by a neurologist according to the McDonald criteria. The inclusion criteria were set as: clinically definite MS with an expanded disability status scale (EDSS) score ≤5.5 and without history of other chronic disorders. The MS patients was comprised of three clinical subtypes: relapsing remitting-MS (RR-MS, n=45, 62.5%), secondary progressive-MS (SP-MS, n=12, 16.5%) and primary progressive - MS (PP-MS, n=15, 21%). The serum vitamin D, haptoglobin, Interleukin 1-beta (IL-1β) and Tumor necrosis factor-alpha (TNF-α) levels were measured by immunoassay.
Results: The MS patients consisted of 76.2% (n=54) female with a mean age of 34.78±8.89 years and the mean disease of 7.02±5.41 years (mean±SD). In subgroups, there was no significant difference between RR-MS, SP-MS and PP-MS, regarding age (P=075), sex (p=0.23), body mass index (p=.63), and duration of disease (p=0.40).
There were not any significant correlations between haptoglobin levels and age and duration of diseases and IL-1β and TNF-α levels in each sub-group (p>0.05).
Notably, in RR-MS patients, there was negative correlation between circulating vitamin D and haptoglobin (p=0.005, r=-0.43). The result remained significant even after adjustment for age, and sex (p=0.03).
Conclusion: Our data suggest the negative correlation between circulating vitamin D and haptoglobin concentration in RR-MS patients may be explained by anti-inflammatory effect of vitamin D. The results will be helpful to explore the new therapeutic targets in MS patients.
Disclosure: Zhila Maghbooli: I have no conflict of interest to declare.
Yasaman Aghababaei: I have no conflict of interest to declare.
Arash Hossein-nezhad: I have no conflict of interest to declare.
Mohammad Ali Sahraian : I have no conflict of interest to declare.
Abstract: EP1473
Type: Poster Sessions
Abstract Category: Pathology and pathogenesis of MS - Immunology
Background: Evidence continues to accumulate supporting a protective role for vitamin D in multiple sclerosis (MS) risk and progression. However, whether vitamin D immunomodulatory effects can be translated into clinical benefits in patients with MS is still a matter of debate. Finding modulator factors in relation to vitamin D an MS could be helpful for clinicians to optimize individual therapies. We aimed to investigate association between circulating levels of vitamin D and haptoglobin as mediators in inflammatory and autoimmune pathways in different types of MS.
Methods: This crass-sectional study enrolled 72 MS patients. The diagnosis of MS was made by a neurologist according to the McDonald criteria. The inclusion criteria were set as: clinically definite MS with an expanded disability status scale (EDSS) score ≤5.5 and without history of other chronic disorders. The MS patients was comprised of three clinical subtypes: relapsing remitting-MS (RR-MS, n=45, 62.5%), secondary progressive-MS (SP-MS, n=12, 16.5%) and primary progressive - MS (PP-MS, n=15, 21%). The serum vitamin D, haptoglobin, Interleukin 1-beta (IL-1β) and Tumor necrosis factor-alpha (TNF-α) levels were measured by immunoassay.
Results: The MS patients consisted of 76.2% (n=54) female with a mean age of 34.78±8.89 years and the mean disease of 7.02±5.41 years (mean±SD). In subgroups, there was no significant difference between RR-MS, SP-MS and PP-MS, regarding age (P=075), sex (p=0.23), body mass index (p=.63), and duration of disease (p=0.40).
There were not any significant correlations between haptoglobin levels and age and duration of diseases and IL-1β and TNF-α levels in each sub-group (p>0.05).
Notably, in RR-MS patients, there was negative correlation between circulating vitamin D and haptoglobin (p=0.005, r=-0.43). The result remained significant even after adjustment for age, and sex (p=0.03).
Conclusion: Our data suggest the negative correlation between circulating vitamin D and haptoglobin concentration in RR-MS patients may be explained by anti-inflammatory effect of vitamin D. The results will be helpful to explore the new therapeutic targets in MS patients.
Disclosure: Zhila Maghbooli: I have no conflict of interest to declare.
Yasaman Aghababaei: I have no conflict of interest to declare.
Arash Hossein-nezhad: I have no conflict of interest to declare.
Mohammad Ali Sahraian : I have no conflict of interest to declare.